- A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 Academic Article GET IT
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Times cited: 70